Ad-blocker Detected - Your browser has an ad-blocker enabled, please disable it to ensure your attendance is not impacted, such as CPD tracking (if relevant). For technical help, contact Support.
In this session we will hear from emerging women leaders in prostate cancer including highlights in prostate cancer research from 2021, treatment of castrate-resistant prostate cancer and genomics for early detection of prostate cancer.
This session is sponsored byAstraZeneca. Chat to the team in the catering breaks byclicking here
Whilst most of the change in prostate cancer management has been in the metastatic setting, even the treatment of localized disease is evolving. Local and international speakers will cover wide ranging topics, including PSMA PET imaging in the diagnosis of local disease, optimizing the delivery of radiation, the role of pelvic lymphadenectomy in the PSMA PET era and whether or not there is still a role for adjuvant radiation.
This session is sponsored byAstellas.Chat to the team in the catering breaks byclicking here
PSMA PET has rapidly altered our understanding of the biology of prostate cancer since its introduction just over 5 years ago. Australia has been at the forefront of the PSMA PET revolution, but international experience has rapidly caught up with the publication of several key studies that form the basis for this important session. Local and international speakers will update us on the current state of play and how to best utilize PSMA PET imaging in both early and advanced metastatic disease.
This session is sponsored byJanssen.Chat to the team in the catering breaks byclicking here
